The use of a mitoxantrone preparation in the preparation of a drug for diagnosing and treating breast cancer. Provided is the use of mitoxantrone and/or a pharmaceutically acceptable salt thereof in the preparation of a lymphatic tracer in a disease associated with breast resection. No local or systemic toxic and side effects are seen after local injection of the preparation, suggesting that the preparation has good tolerance, effectiveness and safety, which provides a new treatment idea for thoroughly curing breast cancer in a breast cancer patient.

The present invention related to a combination of radium-224 (.sup.224Ra) and/or progeny of .sup.224Ra, and a DNA repair inhibitor for use in the treatment of cancer. The DNA repair inhibitor can for example be a poly (ADP-ribose) polymerase inhibitor (PARPi), a MGMT inhibitor, a DNA-dependent protein kinase inhibitor (DNA-PK inhibitor), an ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, an ataxia telangiectasia mutated (ATM) kinase inhibitor, a Wee1 kinase inhibitor, or a checkpoint kinase 1 and 2 (CHK 1/2) inhibitor. The radium-224 (.sup.224Ra) and/or progeny of .sup.224Ra can be comprised in nano- and/or micro sized particles.

Described are methods for preparing radionuclides, such as radionuclides having a high specific activity. The disclosed methods include irradiating target nuclide materials, in solution, with a neutron source. The radionuclides can be separated from the target nuclide material by providing a solid carbon nanostructured material, as a suspension of solids, proximal to the target nuclide material in solution and using the recoil to drive adsorption of the radionuclide onto the solid carbon nanostructured material to transfer the radionuclides from the liquid phase (in solution) to the solid phase (adsorbed to the suspended solid carbon nanostructured material). One or more surfactants can be incorporated into the solution to facilitate formation of a stable suspension of the solid carbon nanostructured material.

A method of preparing a radioactive yttrium phosphate particle suspension.

A method of preparing a radioactive yttrium salt particle suspension comprising multiple steps comprising: using a hydrothermal process wherein a solution of soluble yttrium salt, from the group of yttrium chloride, yttrium nitrate, yttrium sulfate, and yttrium bromide is combined with a solution of sodium phosphate having a stoichiometric excess of phosphate and a preferred pH when combined.

Alpha-emitting LIPIODOL® emulsions and their use in treating cancer is disclosed. Radionuclides, including, but not limited to actinium-225 and bismuth-212/lead-212, are incorporated in LIPIODOL® emulsions. The alpha-emitting LIPIODOL® emulsions can be used to treat primary and metastatic liver cancer, including hepatocellular carcinoma (HCC), and metastatic diseases of the liver, as well as lymphatic cancers.

The present invention is directed to additive manufacturing compositions and methods for producing additive manufacturing composite blends with oxidized discrete carbon nanotubes with dispersion agents bonded to at least one sidewall of the oxidized discrete carbon nanotubes. Such compositions are especially useful when radiation cured, sintered or melt fused.

A method of preparing a radioactive yttrium phosphate particle suspension.

The present application is in the field of imaging reagents. In particular, the present application relates to labelled fluorocarbon imaging reagents, the preparation of the reagents, and their uses for imaging such as PET scanning.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.